Show Summary Details
Page of

(p. 1) Challenges to Implementing Evidence-Based Treatments 

(p. 1) Challenges to Implementing Evidence-Based Treatments
(p. 1) Challenges to Implementing Evidence-Based Treatments

Jack M. Gorman

and Peter E. Nathan

Page of

PRINTED FROM OXFORD CLINICAL PSYCHOLOGY ONLINE ( © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Clinical Psychology Online for personal use (for details see Privacy Policy and Legal Notice).

date: 28 October 2020

This chapter undertakes a detailed examination of two of the most significant issues raised by critics of DSM-5. The first recognizes the continued absence of viable biomarkers of specific diagnoses, despite intense efforts by neuroscientists to identify such markers. The second question concerns what many critics view as the inordinate influence of the pharmaceutical industry-“Big Pharma”-on the highly troubling problem of overdiagnosis that began with DSM-III.

Access to the complete content on Oxford Clinical Psychology requires a subscription or purchase. Public users are able to search the site and view the abstracts and keywords for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.